Showing 7,361 - 7,380 results of 7,701 for search '"Beijing"', query time: 0.08s Refine Results
  1. 7361
  2. 7362
  3. 7363
  4. 7364
  5. 7365
  6. 7366
  7. 7367

    The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors by Xin Y, Liu N, Peng G, Huang X, Cao X, Zhou X

    Published 2025-01-01
    “…Yujing Xin,1 Ning Liu,2 Gang Peng,3 Xiaoyu Huang,3 Xiaojing Cao,3 Xiang Zhou3 1Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People’s Republic of China; 2School of Software, Shandong University, Jinan, Shandong, 250101, People’s Republic of China; 3National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaCorrespondence: Xiang Zhou, Email zhou.xiang@yeah.netPurpose: To investigate the prognostic value of inflammatory indexes based on peripheral blood cells in unresectable hepatocellular carcinoma (HCC) patients treated with Lenvatinib combined with PD-1 inhibitors.Methods: This study retrospectively collected baseline inflammatory indexes from HCC patients received Lenvatinib and PD-1 inhibitor-based combination therapy at the Cancer Hospital of the Chinese Academy of Medical Sciences between October 2018 and October 2021. …”
    Get full text
    Article
  8. 7368
  9. 7369
  10. 7370
  11. 7371
  12. 7372
  13. 7373
  14. 7374
  15. 7375
  16. 7376
  17. 7377
  18. 7378
  19. 7379
  20. 7380